Market Overview

Vilacto Bio Inc. Begins Development of the Vilacto Bio Skincare Knowledge Center

Share:

COPENHAGEN, Denmark, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTCQB:VIBI), today announced that it has commenced development of the Vilacto Bio Skincare Knowledge Center, an online resource that will gather skincare knowledge, science, insights and tips from scientists, dermatologists, podiatrists and other specialists around the world.  Skin challenges often stem from issues existing deeper in the layers of the tissue, not on the surface, minimizing the impact of traditional skin creams.  The tips and guides presented in the Vilacto Bio Knowledge Center will be shared with industry magazines globally, as well as with Vilacto customers.  The Vilacto Bio Knowledge Center is expected to enhance dialogue among specialists and consumers, improve outcomes and drive higher traffic to Vilacto's commercial website.

"We expect to launch the Vilacto Bio Skincare Knowledge Center in the second quarter of 2018, with a goal of encouraging important dialogue between specialists and skincare product end-users.  In addition to increasing overall consumer awareness of the trends and science behind effective skincare, we intend to provide specific guides for a variety of skin conditions, such as those encountered by diabetics and psoriasis patients," stated Gert Anderson, CEO of Vilacto Bio Inc.

About Vilacto Bio Inc.:

Vilacto Bio Inc. (OTCQB:VIBI) is a cosmeceutical and biotech company that has exclusive rights to the fully patented Lactoactive® molecule, which in numerous studies has demonstrated above average effect in treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. The Company also developed and markets a consumer skincare line under the Vilact® trademark.  The Company aims to further develop its Lactoactive® molecule for the purpose of increasing the quality of its retail and medical skin cream products as well as licensing its Lactoactive® molecule to the pharmaceutical industry.

Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved
Denmark

Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com     

Source: Vilacto Bio Inc.

Forward-Looking Statements & Disclaimers:

The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Primary Logo

View Comments and Join the Discussion!